Hims & Hers

Overview

Hims & Hers Health, Inc. is a publicly traded telehealth company founded in 2017 and headquartered in San Francisco. The company reported over 2.5 million subscribers as of late 2025 and has invested more than $300 million in compounding and manufacturing facility infrastructure over the past three years.

On February 23, 2026, CEO Andrew Dudum confirmed during the company’s Q4 2025 earnings call that Hims & Hers is actively developing a peptide-based product line. This wasn’t speculative — the company had already acquired a US-based peptide manufacturing facility in California in February 2025, following previous acquisitions of 503A and 503B compounding facilities.

When HHS Secretary Kennedy announced the peptide reclassification four days later on February 27, HIMS stock surged 7.6% as investors connected the regulatory shift to the company’s peptide positioning.

Why Hims & Hers Matters for the Peptide Market

This is the first publicly traded company with Wall Street analyst coverage to commit to building peptide manufacturing capacity. The significance extends beyond the company itself:

Institutional legitimacy: When a NYSE-listed company with quarterly SEC filings enters a market, it signals that the market is becoming a mainstream healthcare category rather than a grey-market curiosity.

Quality infrastructure: Hims & Hers’ compounding facilities operate under FDA oversight with cGMP (current Good Manufacturing Practice) standards. This is fundamentally different from grey-market vendors sourcing APIs from unverified Chinese suppliers.

Physician oversight model: The telehealth consultation → physician prescription → licensed pharmacy compounding → delivery pipeline is the model regulators want to see. It’s also the model that makes the “research use only” grey-market pathway increasingly indefensible.

What We Know About Their Peptide Plans

Confirmed: Peptide product line in development; California manufacturing facility operational; 503A and 503B pharmacy licenses held.

Not yet confirmed: Which specific peptides will be offered; pricing; launch timeline; whether availability depends on formal FDA reclassification of Category 2 peptides.

Likely: BPC-157 and other Category 1 peptides (once reclassified) would be among the first offerings. GLP-1 products are already part of their business through FDA-approved semaglutide and tirzepatide prescriptions.

Scoring

Transparency (80/100): As a publicly traded company, Hims & Hers files quarterly 10-Q and annual 10-K reports with the SEC. Financial data, subscriber counts, facility investments, and strategic direction are all public record. Manufacturing facilities are identified. This is a level of corporate transparency no grey-market vendor can match. Deducted points: specific peptide product details, sourcing, and testing protocols for the new peptide line are not yet public.

Testing & Quality (75/100): cGMP manufacturing facilities operating under FDA oversight. 503A and 503B pharmacy licenses provide regulatory framework for quality controls. However, specific testing protocols for their peptide line have not been disclosed, and no independent Finnrick-type data exists for their compounded products (expected, since they’re launching a new line). Score reflects the infrastructure rather than product-specific verification.

Pricing (60/100): Historical pricing for their GLP-1 and other telehealth products has been competitive but not the cheapest option. Compounded semaglutide pricing has been a strength. Peptide pricing is not yet announced. The telehealth consultation fee adds cost that grey-market direct-purchase avoids — but also adds physician oversight that grey-market purchases lack.

Reputation (85/100): Over 2.5 million subscribers. Publicly traded since 2021. Coverage from major financial and health media. BBB accredited. Trustpilot reviews are mixed (common for large telehealth platforms) but the subscriber count speaks to market validation. No significant regulatory controversies for the core telehealth business.

Compliance (90/100): This is the strongest dimension. Licensed 503A and 503B compounding facilities, physician-supervised prescriptions, FDA-regulated manufacturing, SEC reporting requirements, and legal counsel appropriate for a public company. No FDA warning letters. Operating within the regulatory framework rather than around it. Score deducted because peptide-specific compliance (once launched) is untested.

Grade: B+

Category	Score	Weight	Weighted
Transparency	80	20%	16.0
Testing	75	25%	18.75
Pricing	60	15%	9.0
Reputation	85	20%	17.0
Compliance	90	20%	18.0
Total			78.75 → B+

The PeptideExaminer Verdict

Hims & Hers represents a fundamentally different category from the grey-market vendors that make up most of our directory. The scoring methodology captures this: the compliance and transparency scores are among the highest we’ve assigned, because the company operates within the regulatory framework by design.

The main uncertainties are product-specific: which peptides, at what prices, with what specific quality controls, and on what timeline. These are “wait and see” questions, not red flags.

For consumers, the critical question is whether Hims & Hers can offer peptides at prices competitive enough to draw people away from grey-market sources. The grey market’s primary advantage has always been access and price. If Hims & Hers can narrow that gap while providing physician oversight, quality controls, and legal protection, the value proposition for grey-market purchasing weakens significantly.

We will update this profile as the peptide product line launches and we have product-specific data to evaluate.

---

Sources: Hims & Hers Q4 2025 earnings call transcript (February 23, 2026), SEC filings, company press releases, BBB records, Trustpilot.